Senior Scientist Alex Margiott will be presenting at the Zemax Envision 2020 Virtual Conference, with a talk on October 6th, about Triple Ring’s Monte Carlo GPU-optimized light-tissue simulation, uniquely integrated with OpticStudio, for dramatically faster ray tracing, allowing for rapid design iteration and optimization in-silica.
Triple Ring Technologies, a co-development firm that helps innovators and entrepreneurs develop breakthrough science-based technologies, is pleased to announce the addition of Greg Kovacs, MD, Ph.D., as Chief Medical Officer. In this role, Kovacs will lead efforts to turn engineering advances into meaningful clinical solutions that improve patient outcomes and achieve commercial success. Areas of focus include medical electronics, wearable devices, microfluidics, and medical systems engineering.
“We are thrilled to have Greg join the Triple Ring team,” said Joe Heanue, Ph.D., CEO. “He is tremendously well-respected for his innovation at the boundaries of engineering, life sciences, and medicine. We’re confident that his energy and insight will be invaluable as we partner with our clients to solve hard problems, develop new products, and launch new ventures. I’m also very pleased that he will be a key mentor to the younger engineers and scientists who are drawn to Triple Ring as a great place to work on a variety of challenging projects at the start of their careers.”
Kovacs has a long list of distinguished accomplishments spanning academia, industry, and government service. He is an Emeritus Professor of Electrical Engineering at Stanford University, and for years had a courtesy appointment in the Department of Medicine, Division of Cardiovascular Medicine. His research at Stanford included the development of non-invasive instruments for cardiovascular medicine; microfabricated sensors; analog electronics; titration of medical care via embedded systems; and remote delivery of laboratory electronics education. He co-founded the Bioengineering Department and led the initial development of the bioengineering graduate core curriculum sequence. Kovacs has published over 180 peer-reviewed articles, has been granted 72 patents, and has designed a large number of electronic circuits and systems.
Kovacs has extensive industry experience co-founding companies, including Cepheid, which has shipped several hundred million nucleic acid diagnostics, and PhysioWave, developer of noninvasive cardiovascular risk assessment devices. He was a founder and Chief Technical Advisor of Malibu IQ, a private equity fund created to commercialize the intellectual property portfolio of HRL (formerly Hughes Research Laboratories).
Kovacs has a rich history of service to DoD, DoE, NASA and other government agencies. In 2003, he served as the Investigation Scientist for the debris team of the Columbia Accident Investigation Board at the Kennedy Space Center, Florida, then as Engineering/Medical Liaison on the Spacecraft Crew Survival Integration Investigation Team (SCSIIT) of the Johnson Space Center. From 2008 through 2010 he was Director of the Microelectronics Technology Office at DARPA, leading deployment of a total $1.6B for DoD-relevant and basic-science research.
“I am absolutely delighted to be joining Triple Ring as CMO,” said Kovacs. “It is the job I was made for, and it allows me to bring my background in engineering and medicine to bear on meaningful clinical problems, hopefully seeing them through to clinical use. The best part, though, is the brilliant, yet humble, and friendly team, and the open, collaborative environment at Triple Ring.”
Triple Ring Technologies is a co-development company, partnering with clients, primarily in medtech and life sciences, to create new technologies, launch innovative projects, and start new ventures. Their capabilities span strategic investment, incubation, early R&D, product development, manufacturing, regulatory approval, and market access. They have personnel nationwide, including offices in Silicon Valley & Boston.
See the full press release:
The Triple Ring team will be participating in the upcoming 4D Meets AI – Advancing Drugs, Devices, Diagnostics, and Digital Health through the Power of Artificial Intelligence virtual partnering conference by Life Science Nation, September 17-18.
People are used to seeing graphs (plots) of Y vs. X: temperature vs. day of the week; or GDP vs. year. Given that training, why are plots of COVID-19 so hard to grasp? I think I observed something that may help to understand this difficulty.
Let us have a “gedanken” pandemic. Let us suppose that a disease breaks out that has a doubling time of 9 days. So, on day 0 we have one patient, and every 9 days we end up with twice the number we had before. After a full 10 weeks, we would have seen fewer than 250 patients. Looking at the plot below, I see that, while things are accelerating, all I have to do is “lift my foot off the pedal” and things will calm down. Seems like something I’ve seen before.
Now, let’s wait for 10 more weeks. We see:
Here’s my observation: the world of 10 weeks ago is unrecognizable. This feels true. Think back to March. Can you remember what life was like before COVID? For me, not really. How different was the daily news broadcast in April? Exponential growth has created a world that didn’t exist 10 weeks ago.
The same effect occurs with respect to resources to cope with the pandemic. Suppose we can provide beds for 10000 COVID patients.
Even at week 15, we’ve got more than 3 times the number of beds (the red line) that we need (the blue line).
Now, wait 5 weeks.
Our capability has been crushed.
Should we have capacity of 50000 beds? At week 15, with 3300 cases, that would have seemed ridiculous and wasteful. But wait two more weeks:
Our ridiculous over-planning has been crushed just as easily.
There are two other destructive phenomena that involve exponential growth: a plague of locusts, and nuclear weapons. In all these cases, even unreasonable expectations of the world are destroyed by reality.
It is said that people will get used to what COVID does. I claim, not. I claim the opposite: people will be repetitively stunned by what happens.
The only way to prevent any of this is to prevent exponential growth. Right now (21 July), the USA is failing to do that.
A word about how I’ve plotted things: I made the time axis occupy the same space on the page no matter its actual duration. That may be thought of as a cheat. But not if you consider that we’re trying to understand an “event” like COVID-19. The takeaway, to me, from above, is that the “event” breaks apart into “now” vs. “forever ago”: the past three weeks are a brand new bad world, and the next 3 weeks will be shockingly, unimaginably worse.
The doubling time of 9 days is short by present standards. But periods of such growth have existed and could again. It is not impossibly quick.
Eventually, we would run out of people to get sick. But right now slightly over 1% of the US population has been sick. That leaves almost 99% available to get sick: approximately an unlimited supply.
Can you imagine the present situation being 10 times worse? Or just 3 times worse (Florida would have 60000 in the hospital and 15000 dead)? No, you can’t. We have no other option than to slow, stop, and finally reverse the growth.
April 21, 2020 (Newswire.com) – Triple Ring Technologies, a science-driven co-development company, today announced the opening of a new, enhanced biosafety laboratory (BSL) at its Newark, CA, headquarters to accommodate the development of cutting-edge diagnostics and therapeutics for the fight against the COVID-19 pandemic
Read more at: https://www.newswire.com/news/triple-ring-technologies-and-evolve-manufacturing-provide-vital-21132163?
We’ll be there March 17th and 18th.
Newark, CA – December 2, 2019 – Triple Ring Technologies, a co-development company working at the intersection of high tech and life science, announces today that they are entering into a collaborative agreement with Evolve Manufacturing Technologies to better serve both companies’ clients with services ranging from concept generation to commercialization.
With both companies headquartered in Silicon Valley, Triple Ring and Evolve will work closely to ensure that new medical and life-science products can be efficiently and quickly transferred to a robust, high-quality manufacturing line. A jointly run New Product Introduction (NPI) lab will support this process.
“The Evolve Manufacturing partnership will allow us to meet the needs of customers who want to launch technically sophisticated products,” said Joseph Heanue, President and CEO of Triple Ring Technologies. “The streamlined services from both companies will help both our start-up and Fortune 500 customers get to market faster.”
Founded in 1999, with a focus on Medical Devices, Life Science, and Imaging, Evolve operates a 75,000 square-foot state-of-the-art manufacturing facility with separate class 7 & 8 clean rooms as well as an on-site inspection team to assure quality. Evolve specializes in precision mechanical and electromechanical assembly, microfluidics, integration to full system builds, disposables, and sterile devices. Evolve is an FDA-registered establishment with ISO 13485-2016.
“The Evolve team is very enthusiastic about this partnership,” said Noreen King, CEO and Founder of Evolve Manufacturing. “With Triple Ring, we are able to give our customers an optimal transition from initial concept through the life of the product without compromise.”
About Triple Ring Technologies
Triple Ring Technologies is a co-development company. We stand alongside our clients to solve difficult problems, develop breakthrough products, and create new companies at the intersection of high-tech and life sciences. With a deep level of expertise and commitment from our team of professionals, we invest in our work, because we don’t succeed until our clients succeed. www.tripleringtech.com
About Evolve Manufacturing
Evolve Manufacturing Technologies is a leading contract manufacturer of medical devices, life science tools and imaging systems. Based in Silicon Valley with Class 7 and Class 8 cleanrooms, Evolve can provide a broad array of manufacturing services for Class I, II and III devices; from large scale capital equipment to sterile surgical kits. www.evolvemfg.com